<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(3)</volume><submitter>Bloom PP</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites that may be beneficial in HE. We evaluated the safety and efficacy of VE303 to treat HE.&lt;h4>Methods&lt;/h4>We performed a single-center, randomized, placebo-controlled trial of VE303 in adult patients with a history of overt HE (NCT04899115). Eligible patients were taking lactulose and rifaximin, had no recent systemic antibiotics, and had MELD ≤20. All patients received 5 days of oral vancomycin followed by randomization to 14 days of VE303 or placebo (2:1). The primary endpoints were incidence of serious adverse events and change in psychometric HE score (PHES) from baseline to 4 weeks </pubmed_abstract><journal>Hepatology communications</journal><pagination>e0650</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11841841</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.</pubmed_title><pmcid>PMC11841841</pmcid><pubmed_authors>Silber JL</pubmed_authors><pubmed_authors>Crossette E</pubmed_authors><pubmed_authors>Young VB</pubmed_authors><pubmed_authors>Norman JM</pubmed_authors><pubmed_authors>Lok ASF</pubmed_authors><pubmed_authors>Bloom PP</pubmed_authors><pubmed_authors>Bassis CM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.</name><description>&lt;h4>Background&lt;/h4>Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites that may be beneficial in HE. We evaluated the safety and efficacy of VE303 to treat HE.&lt;h4>Methods&lt;/h4>We performed a single-center, randomized, placebo-controlled trial of VE303 in adult patients with a history of overt HE (NCT04899115). Eligible patients were taking lactulose and rifaximin, had no recent systemic antibiotics, and had MELD ≤20. All patients received 5 days of oral vancomycin followed by randomization to 14 days of VE303 or placebo (2:1). The primary endpoints were incidence of serious adverse events and change in psychometric HE score (PHES) from baseline to 4 weeks </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-06-06T23:32:23.914Z</modification><creation>2026-06-06T03:10:55.497Z</creation></dates><accession>S-EPMC11841841</accession><cross_references><pubmed>39969428</pubmed><doi>10.1097/HC9.0000000000000650</doi></cross_references></HashMap>